Clinical Research Directory

Inclusion Criteria: * Age 18-75 years old; * Patients diagnosed with glioma by histology, patients with progress in first-line therapy, including postoperative recurrence, progress in first-line standard therapy, and patients unable to undergo surgery/radiotherapy; * no previous treatment with irinotecan or irinotecan liposomes; * At least one measurable or evaluable lesion according to RANO criteria; * ECOG score is 0\~1; * Good bone marrow and organ function: ① Neutrophils (ANC) ≥1.5×109/L, platelets (PLT) ≥100×109/L, hemoglobin (Hb) ≥90g/L, white blood cells (WBC) ≥3.0×109/L, albumin (ALB) ≥32 g/L, and no bleeding tendency; ② AST, ALT and alkaline phosphatase (ALP) were all ≤2.5× upper limit of normal range (ULN), and ≤5×ULN when liver metastases occurred; Total bilirubin ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance ≥60 ml/min (calculated according to Cockroft-Gault); * Expected survival ≥3 months; * Can understand the situation of this study, patients and (or) legal representatives voluntarily agree to participate in this study and sign informed consen; Exclusion Criteria: * Patients allergic to the investigational drug and its excipients; * Known or suspected central nervous system metastasis; * The use of potent depressants or inducers of CYP3A, CYP2C8, and UGT1A1 (anticonvulsants \[phenytoin, phenobarbital, or carbamazepine\], rifampicin, rifambutin, St.John's.) could not be discontinued or were not discontinued within 2 weeks prior to enrollment Wort\], grapefruit juice, clarithromycin, itraconazole, Lopinavir, Nefazodone, Nelfinavir, Ritonavir, Saquinavir, Terrapivir, voriconazole, Azanavir, Gefilozil, indinavir, etc.); * There are signs and symptoms of intestinal obstruction; * have had other malignant tumors within the past 5 years or currently, except for cured cervical carcinoma in situ, uterine carcinoma in situ and non-melanoma skin cancer; * Pregnant or lactating female patients, patients of childbearing age who refuse to accept contraceptive measures; * Patients considered by the investigator to be unsuitable for this study.